BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
39 hedge funds and large institutions have $8.24M invested in BRAINSTORM CELL THERAPUTC in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
8% more capital invested
Capital invested by funds: $7.61M → $8.24M (+$628K)
5% more funds holding
Funds holding: 37 → 39 (+2)
0.03% more ownership
Funds ownership: 0.59% → 0.63% (+0.03%)
95% less call options, than puts
Call options by funds: $107K | Put options by funds: $2.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$341K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$295K |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$295K |
| 4 |
Renaissance Technologies
New York
|
+$286K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$622K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66K |
| 3 |
Wolverine Trading
Chicago,
Illinois
|
-$65.8K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$62.8K |
| 5 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
-$16.9K |
BCLI Hedge Fund Activity: Q3 2019 in Review
39 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2019, worth a combined $8.24M — up 8.3% from $7.61M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BCLI positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Raymond James & Associates, opening a new position worth an estimated $341K. The largest seller was Sabby Management, exiting entirely with an estimated $622K sold.
- 39 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2019, up from 37 in Q2 2019.
- Funds reported $8.24M of BRAINSTORM CELL THERAPUTC stock for Q3 2019, up 8.3% quarter-over-quarter.
- 6 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2019 and 3 closed out, a net change of +3 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2019 was Raymond James & Associates, an estimated $341K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2019 was Sabby Management, an estimated $622K sold.
Based on aggregated 13F filings for Q3 2019.